About InVivoSIM anti-human EGFR x MET (Amivantamab Biosimilar) This biosimilar antibody uses the same variable regions as the therapeutic antibody Amivantamab, making it ideal for research use. Amivantamab is a fully human IgG1 bispecific monoclonal antibody that simultaneously targets the epidermal growth factor receptor (EGFR) and c‑Met (MET). By binding to these receptors, it blocks ligand binding and promotes receptor internalization and degradation. Clinically, Amivantamab is approved for the treatment of adults with non–small-cell lung cancer (NSCLC) bearing EGFR exon 20 insertion mutations, especially following disease progression after platinum-based chemotherapy. This Amivantamab biosimilar is intended only for research use, and is well suited for studying mechanisms of receptor blockade, receptor downmodulation, and immune effector activation in EGFR- and MET-driven tumor models. InVivoSIM anti-human EGFR x MET (Amivantamab Biosimilar) Specifications IsotypeHuman IgG1, κ Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer Reported Applicationsin vivo functional assays in vitro functional assays FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
